Tweet by ScienceofParkinsons on Twitter Posted byJoseph Thornton MDMay 10, 2022Posted inBlog ScienceofParkinsons @ScienceofPD WOW – A Phase 3 randomized clinical trial enrolling 130 participants with early-stage #ALS & moderate progression rate finds ultrahigh-dose methylcobalamin (vitamin B₁₂) significantly slowed progression (ALSFRS-R total score) over 16-week study jamanetwork.com/journals/jaman… pic.twitter.com/jOA1Q1zbj6 5/10/22, 7:46 AM Share this: Share on X (Opens in new window) X Share on Facebook (Opens in new window) Facebook Like Loading... Related Published by Joseph Thornton MD Teacher, Clinical Supervisor, [AIdvisor] Retired Clinical Associate Professor, Psychiatry, University of Florida Affiliation is for identification only. All content and opinions are my own. View more posts
Gator Psychiatry 